Announced Fri, 7 Aug, 2026 · 14:39 IST
Board approves Q1 FY27 results; loss of Rs 33.62 lakh
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reactionminutes from the announcement price · days from the prior close
—Next day
—
prior close
₹143.90
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.0%—
Computers - Software & Consulting peers, median of 66sector+0.1%—
Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
+0.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
—+0.0—+0.0—
Next day
—-0.0—+0.1—
2d
—-0.2—+0.0—
3d
—+0.2—-0.7—
4d
—+0.3—-0.2—
5d
—+0.4—-0.5—
1w
—+0.9—-3.8—
15d
—+1.6—-1.9—
1m
—+2.0—-4.5—
2m
—+0.6—-10.6—
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Computers - Software & Consulting peers, median of 66Pending
Minute windows have no benchmark: there is no intraday index history to compare against.
AI summary
iSERA Lifesciences (formerly Covidh Technologies) board approved Q1 FY27 unaudited results. Revenue from operations is zero. Net loss widened to Rs 33.62 lakh from Rs 1.59 lakh in Q1 FY26. Other income at Rs 5.77 lakh. Total expenses rose to Rs 33.62 lakh from Rs 15.4 lakh YoY. Reserves remain negative at Rs 43.81 lakh. Auditor GMKS and Co gave an unmodified limited review report.
Likely market impact
Zero operating revenue and widening losses with negative reserves raise sustainability concerns. No adverse audit remarks.